We are live on ! Find out more
IDXG

Interpace Biosciences, Inc. Common Stock
IDXG

Delisted

IDXG was delisted on the 24th of February, 2021.

Back to rankings

3 hedge funds and large institutions have $58K invested in Interpace Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% less funds holding

Funds holding: 12 → 3 (-9)

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

93% less capital invested

Capital invested by funds: $849K → $58K (-$791K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
-9
Holders Change %
-75%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$49.1K
2
RG
Retirement Group
California
+$4.41K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$368K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$253K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$101K
4
Squarepoint
Squarepoint
New York
-$65K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$40K

IDXG Hedge Fund Activity: Q1 2021 in Review

3 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2021, worth a combined $58K — down 93% from $849K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of IDXG and 2 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $49.1K. The largest seller was BlackRock, exiting entirely with an estimated $368K sold.

  • 3 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2021, down from 12 in Q4 2020.
  • Funds reported $58K of Interpace Biosciences, Inc. Common Stock stock for Q1 2021, down 93% quarter-over-quarter.
  • 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2021 and 11 closed out, a net change of -9 holders.
  • The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2021 was HRT Financial, an estimated $49.1K added.
  • The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2021 was BlackRock, an estimated $368K sold.

Based on aggregated 13F filings for Q1 2021.